[ad_1]
Russian scientists released the first report on the new coronavirus vaccine they developed, saying that preliminary studies showed signs of an immune response.
A report published in the medical journal “The Lancet” stated that all people who were tested for the vaccine produced antibodies against the virus without serious side effects.
Before the study results were published, Russia had approved a vaccine license last month and was the first country in the world to have a new coronavirus vaccine license.
However, experts say Russia’s vaccine trials are too small to show that the vaccine is effective and safe. Some Western scientists worry that Russia is developing vaccines too fast and may be suspicious of taking shortcuts.
However, Russia refutes external criticism. President Putin stated that the vaccine has passed all the necessary tests and that one of his own daughters has also received the vaccine.
What does the report say?
The vaccine developed by Russia is called Sputnik-V and it has been tested in humans twice in June and July this year.
The report published in The Lancet indicated that a total of 38 people participated in the trial and each received a dose of the vaccine, followed by an additional dose three weeks later.
The subjects were between 18 and 60 years old and were observed for 42 days after receiving the vaccine, all developed antibodies within 3 weeks, the most common side effects were headache and joint pain.
But the vaccine trial did not include a placebo, and all subjects were told they would receive the vaccine.
The report concluded that large-scale long-term trials, including comparison with placebo, and follow-up observations are needed to determine the long-term safety and efficacy of the vaccine against novel coronavirus diseases.
The report says that the third phase of the trial is planned and that 40,000 volunteers of “different ages and levels of risk” will participate.
The vaccine developed in Russia uses an adapted adenovirus strain to trigger an immune response in the human body. Adenovirus usually causes the common cold.
- COVID-19: Shortcuts, Tricks, and Nationalism in the Vaccine Development Contest
- Several questions that interest you in the new corona vaccine research and development sprint
there’s still a long way to go
Philippa Roxby, BBC Health Correspondentanalysis:
The reaction of some British scientists to the Russian vaccine is “encouraging” and “so far so smooth”, but it is clear that the successful development of the vaccine still has a long way to go.
Although all the subjects in the second phase of the test had an antibody response to the vaccine, this does not mean that they will not be attacked by the new coronavirus, which has not been determined.
From current results, we can know that the vaccine appears to be safe in healthy people between the ages of 18 and 60, but it is only determined to be safe for 42 days, and then we won’t know. For people at high risk of contracting the new corona virus, people over the age of 60, and people who have their own health problems, it is not known how safe this vaccine is.
Only after a larger and longer randomized trial (subjects don’t know the eleven seconds they received or a placebo) can the above questions be answered, and scientists can be sure whether the vaccine is really good for the general population . The population is valid.
How did you respond?
Kirill Dmitriev, the investor behind the Russian vaccine, said the vaccine trial report “responded strongly to the skepticism of unreasonable critics.”
He said 3,000 volunteers have been recruited to participate in the next test.
Russian Health Minister Mikhail Murashko said Russia will start vaccination in November or December, targeting high-risk groups first.
But there is still a long way to go before the vaccine is finally available.
According to the World Health Organization, there are currently a total of 176 new research and development programs for vaccines against coronavirus disease in the world, 34 of which have been tested in humans and 8 of them have entered phase three. highest testing.